



REMARKS

The Examiner's Advisory Action dated February 20, 2007, has been carefully considered. In the present application, claims 1 and 8-18 are pending. Claims 1, 13 and 15-18 are rejected. In view of the forgoing amendment and the following remarks, reconsideration and withdrawal of the present basis for rejecting the claims herein of this application is respectfully requested.

I. Discussion of the Amendment



Claim 1 is amended to delete the formula , and the phrase "provided that where R⁰ is a monocyclic or bicyclic 6- to 14-membered aryl, then R⁸ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue".

Claim 13 is amended to have substituents on the imidazole ring of formulae 29 and 30 corresponding to those on the imidazole ring of formula Ib.

Claim 18 is amended to better and more properly reflect what Applicants regard as their invention.


Claims 15-17 are cancelled, without prejudice.


Applicants reserve the right to pursue the cancelled subject matter in a subsequent application.

This amendment to the claims adds no new matter.

II. Discussion of the Rejections on Claims 1, 13 and 15-18

The Examiner rejects claims 1, 13 and 15-18, and specifically asserts that



"Claim 1: formula  and the phraseology

provided that where R⁰ is a monocyclic or bicyclic 6- to 14-membered aryl, then R⁸ is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue render the claim indefinite and must be deleted.

Claims 13, 18: Not within the scope of claim 1. Substitution of imidazole ring is other than in claim 1. The substituents in claim 13 have definitions that are not in claim 1.

Claim 15-16: Are not drawn to practical utilities. It is not clear what applicant means by 'influence blood coagulation [or] fibrinolysis'. One must read the specification into the claims contrary to several US courts' decisions. Such reading of the specification renders the claims duplicated of 17.

Claim 17: While anticoagulant may be used in the course of treating the listed diseases, the anticoagulant does not treat several of the diseases, such as, MI, viral infection, etc. The claim should be drawn to a method of using the compounds as antithrombic agents. No need to list the diseases where thrombosis may occur."
(See the Action, page 2)

Applicants submit that the forgoing amendment has obviated the Examiner's rejection on claims 1, 13 and 15-17.


Furthermore, Applicants respectfully traverse the rejection on claim 18. Applicants submit that claim 18, depending upon claim 1, is within the scope of claim 1. Applicants respectfully request reconsideration and withdrawal of the instant rejection on claim 18.

III. Conclusion

In view of the above remarks, Applicants respectfully submit that the present application is in condition for allowance. Early notice to this effect is, thus, respectfully requested.

If there are any issues that can be resolved by a telephone conference or an Examiner's amendment, the Examiner is invited to call the undersigned attorney at (908) 231-3582.

Respectfully submitted,



Jiang Lin, Registration No. 51,065
Attorney for Applicants

Date: March 9, 2007

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

Docket No. DEAV2002-0085 US NP